Patents Assigned to Gilead Sciences
-
Patent number: 12269812Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: GrantFiled: July 8, 2020Date of Patent: April 8, 2025Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Patent number: 12264173Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.Type: GrantFiled: July 18, 2023Date of Patent: April 1, 2025Assignee: Gilead Sciences, Inc.Inventors: Gregory F. Chin, Byoung-Kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Dustin S. Siegel, Hai Yang
-
Patent number: 12258346Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: December 18, 2023Date of Patent: March 25, 2025Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A Codelli, John H. Conway, Jennifer L Cosman Ellis, Rao V. Kalla, Zachary A Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Patent number: 12240862Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.Type: GrantFiled: December 21, 2021Date of Patent: March 4, 2025Assignee: Gilead Sciences, Inc.Inventors: Daniel H. Byun, Eda Y. Canales, Laurent P. Debien, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Stephane Perreault, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen, Lianhong Xu
-
Patent number: 12227520Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: October 28, 2022Date of Patent: February 18, 2025Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
-
Patent number: 12208110Abstract: The present disclosure relates to compounds of Formula I, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for treatment of viral infections, for example for treatment of paramyxoviridae, pneumoviridae, picornaviridae, flaviviridae, filoviridae, arenaviridae, orthomyxovirus, and coronaviridae infections.Type: GrantFiled: October 15, 2021Date of Patent: January 28, 2025Assignee: Gilead Sciences, Inc.Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
-
Patent number: 12202849Abstract: The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.Type: GrantFiled: August 11, 2022Date of Patent: January 21, 2025Assignee: Gilead Sciences, Inc.Inventors: Chiajen Lai, Bing Shi, Robert G. Strickley
-
Patent number: 12202782Abstract: The present disclosure relates to methods and intermediates for the synthesis of certain compounds that inhibit MCL1, for use in the treatment of cancers.Type: GrantFiled: November 17, 2021Date of Patent: January 21, 2025Assignee: Gilead Sciences, Inc.Inventors: Darryl D. Dixon, Michael A. Ischay, Trevor C. Johnson, Jeffrey E. Merit, Christopher S. Regens, Eric A. Standley, Dietrich P. Steinhuebel
-
Patent number: 12202842Abstract: The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.Type: GrantFiled: March 9, 2023Date of Patent: January 21, 2025Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, Qingming Zhu
-
Patent number: 12195524Abstract: Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.Type: GrantFiled: August 23, 2021Date of Patent: January 14, 2025Assignee: Gilead Sciences, Inc.Inventors: Manuel Baca, Brian A. Carr, Sheila B. Clancy, Craig S. Pace, Heather T. Stephenson, Nathan D. Thomsen
-
Patent number: 12187734Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.Type: GrantFiled: December 22, 2023Date of Patent: January 7, 2025Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwalder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
-
Patent number: 12187753Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.Type: GrantFiled: August 22, 2023Date of Patent: January 7, 2025Assignee: Gilead Sciences, Inc.Inventors: Julie Farand, Tezcan Guney, Darryl Kato, John O. Link, James B. C. Mack, William J. Watkins
-
Patent number: 12180217Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: March 11, 2024Date of Patent: December 31, 2024Assignee: Gilead Sciences, Inc.Inventors: Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L Mackman, Dustin S. Siegel, Xianhuang Zeng
-
Patent number: 12180197Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: March 9, 2022Date of Patent: December 31, 2024Assignee: Gilead Sciences, Inc.Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, Scott D. Schroeder, Nathan D. Shapiro, Suzanne M. Szewczyk, James G. Taylor, Nathan E. Wright, Sheila M. Zipfel
-
Patent number: 12162896Abstract: The present disclosure relates salts and the crystalline forms of certain 3?,4,4?,5-tetrahydro-2H,2?H-spiro[benzo[b][1,4]oxazepine-3,1?-naphthalene] derivatives as well as pharmaceutical formulations and therapeutic uses thereof. The present disclosure also relates to preparing such salts, crystalline forms and pharmaceutical formulations.Type: GrantFiled: May 3, 2023Date of Patent: December 10, 2024Assignee: Gilead Sciences, Inc.Inventors: John Enquist, Michael A. Ischay, Olga V. Lapina, David W. Lin, Christopher S. Regens, David A. Siler, Eric A. Standley, Sarah E. Wortman
-
Patent number: 12162844Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.Type: GrantFiled: March 9, 2023Date of Patent: December 10, 2024Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
-
Patent number: 12161625Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.Type: GrantFiled: November 29, 2022Date of Patent: December 10, 2024Assignee: Gilead Sciences, Inc.Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
-
Patent number: 12139474Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).Type: GrantFiled: May 24, 2023Date of Patent: November 12, 2024Assignee: Gilead Sciences, Inc.Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
-
Patent number: D1063638Type: GrantFiled: April 9, 2024Date of Patent: February 25, 2025Assignee: GILEAD SCIENCES, INC.Inventors: Robert Bridges, Joseph Cordova, Gaurav Dabholkar, Alexandra Fideler, Monica Vazirani
-
Patent number: D1064842Type: GrantFiled: March 30, 2023Date of Patent: March 4, 2025Assignee: GILEAD SCIENCES, INC.Inventors: Robert Bridges, Joseph Cordova, Trevor Zimmermann, Caricia Catalani, Kangil Cheon, Hortense Caroline Agnes Desodt, Jesse Arnold Fourt, Brittany Jeannette Margot
